These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 761447)

  • 21. [Determination of anticoagulant activity of heparin].
    Dalmora SL; Assaf GS; Dalmora ME; Vaucher LC; Vaccari SF
    Rev Hosp Clin Fac Med Sao Paulo; 1991; 46(2):59-62. PubMed ID: 1843369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative study of the effects of 4-chlorophenyl-2-hydroxy-4-oxo-2-butenoate and heparin on blood coagulation].
    Starkova AV; Sobin FB; Syropiatov BIa; Pulina NA
    Eksp Klin Farmakol; 2013; 76(10):25-6. PubMed ID: 24400385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography.
    Gantioqui J; Stevic I; Atkinson H; Chan AKC
    Blood Coagul Fibrinolysis; 2018 Sep; 29(6):521-527. PubMed ID: 29965810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of the clotting system: heparin-coated versus non coated systems for extracorporeal circulation.
    Urlesberger B; Zobel G; Rödl S; Dacar D; Friehs I; Leschnik B; Muntean W
    Int J Artif Organs; 1997 Dec; 20(12):708-12. PubMed ID: 9506788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparin elimination in uraemic patients on Haemodialysis.
    Teien AN; Bjoornson J
    Scand J Haematol; 1976 Jul; 17(1):29-35. PubMed ID: 959771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assay of heparin; influence of various factors on potency and clotting concentration of heparin.
    FOSTER RH
    J Am Pharm Assoc Am Pharm Assoc; 1948 Jun; 37(6):215-22. PubMed ID: 18865169
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.
    Despotis GJ; Summerfield AL; Joist JH; Goodnough LT; Santoro SA; Spitznagel E; Cox JL; Lappas DG
    J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1076-82. PubMed ID: 7983877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properties of a heparin-poly(vinyl alcohol) hydrogel coating.
    Goosen MF; Sefton MV
    J Biomed Mater Res; 1983 Mar; 17(2):359-73. PubMed ID: 6841373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
    Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
    Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
    Zmuda K; Neofotistos D; Ts'ao CH
    Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of heparin and thromboplastin on the half-life of 125I-protein C in the blood flow of rats].
    Kogan AE; Strukova SM
    Biull Eksp Biol Med; 1991 Feb; 111(2):116-8. PubMed ID: 1854945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated clotting time and heparin administration in Sprague-Dawley rats and Syrian golden hamsters.
    Portilla-De-Buen E; Ramos L; Leal C; Garcia D; Rodriguez-Reynoso S; Herta M; Intaglietta M
    Contemp Top Lab Anim Sci; 2004 Mar; 43(2):21-4. PubMed ID: 15053503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of thrombin-receptors of thrombocytes for the interaction of heparins and low-molecular-weight heparin in human whole blood clotting.
    Harenberg J; Schuler M; Zimmermann R; Heptner W
    Haemostasis; 1988; 18 Suppl 3():20-2. PubMed ID: 2840370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Heparin: a significant biological factor].
    Tarnawski A; Wajdowicz A
    Postepy Hig Med Dosw; 1970; 24(1):125-31. PubMed ID: 5457705
    [No Abstract]   [Full Text] [Related]  

  • 37. Animal model for pharmacokinetic approach to individualized heparin dosage regimen for i.v. infusion by constant rate to achieve and maintain a desired clotting time.
    Ritschel WA; Brady ME
    Arzneimittelforschung; 1979; 29(12):1891-4. PubMed ID: 546429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of protease inhibitor (trasylol) and heparin in cardiorespiratory resuscitation. I. Studies of the blood clotting system.
    Gaszyński W
    Anaesth Resusc Intensive Ther; 1975; 3(2):125-34. PubMed ID: 1080969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacology of heparin prophylaxis.
    MacHarg MA; Becht JL
    J Am Vet Med Assoc; 1983 Jul; 183(1):129-30. PubMed ID: 6874519
    [No Abstract]   [Full Text] [Related]  

  • 40. [Preliminary studies of the blood clotting system following heparin administration in inhalations].
    Skarzyńska M
    Pol Arch Med Wewn; 1979 Oct; 62(4):315-20. PubMed ID: 503902
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.